Drug intelligence / Profile preview

BYK 321084

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

BYK 321084 (also known as TAK-084) is a small molecule inhibitor of type 4 cyclic nucleotide phosphodiesterase (PDE4). It was developed for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). PDE4 inhibitors work by blocking the breakdown of cyclic AMP, leading to anti-inflammatory effects in various tissues. The drug was originally developed by Nycomed, which later became part of Takeda[1].

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on BYK 321084.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BYK 321084.

Explore the full profile